Biolegend, 423801, CFSE Cell Division Tracker Kit, 1kit

CFSE Cell Division Tracker Kit is composed of 5 vials, 100 µg per vial of CFSE (formally known as 5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester of CFDA SE), and 500 µl of anhydrous DMSO. CFSE is able to passively diffuse into cells. Inside the cell, its acetate groups are cleaved by intracellular esterases, and the molecules are converted to fluorescent esters. CFSE is retained within the cell and covalently couples to intracellular molecules via its succinimidyl group. Due to this covalent coupling reaction, fluorescent CFSE can be retained within the cell for an extremely long period. Also, due to this stable linkage, once the dye has been incorporated within the cell, it is not transferred to adjacent cells. CFSE is widely used for cell proliferation assays and in vivo cell tracking.
1kit
Preparation: The CFSE Cell Division Tracker Kit is composed of lyophilized CFSE and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 36 µl of DMSO to one vial of CFSE dye until fully dissolved.
Storage & Handling: Store CFSE Cell Division Tracker Kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the CFSE, use immediately, or store at -20°C in a dry place and protected from light, preferably in a dessicator or in a container with desiccant for no more than one month.
Application: ICFC - Quality tested In vivo cell tracking1 - Reported in the literature, not verified in house
Recommended Usage: This lot has been tested by flow cytometric analysis of in vitro cell proliferation assay. It can be used at concentrations ranging from 0.5 - 10 µM for cell labeling. It is recommended that the reagent be titrated for optimal performance for each cell type, culturing condition, or application.
Application Notes: The molecular weight of CFSE is 557.47. The excitation and emission wavelengths of CFSE-labeled cells are 492 nm and 517 nm, respectively. Each 100 µg vial of CFSE may be reconstituted with 36 µl of anhydrous DMSO to yield a stock concentration of 5 mM. Materials Provided: 5 vials x 100 µg CFSE 500 µl anhydrous DMSO CFSE Labeling Procedure: 1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial. 2. Prepare stock solution by reconstituting 1 vial of lyophilized CFSE dye in 36 µL of DMSO to make a 5 mM solution. 3. Prepare a 5 µM working solution by diluting 1 µL of 5 mM CFSE stock solution in 1 mL PBS for every 1 mL of cell suspension (or at an optimal working concentration as determined by titration). 4. Spin down and resuspend cells at 10-100 x 106 cells/mL in the CFSE working solution. 5. Incubate cells for 20 minutes at room temperature or 37°C and keep protected from light. 6. Quench the staining by adding 5 times the original staining volume of cell culture medium containing 10% FBS. 7. Pellet cells and resuspend in pre-warmed cell culture medium. 8. Incubate cells for 10 minutes. 9. After incubation, CFSE labeled cells are ready for downstream applications or analysis.
Additional Product Notes: View more applications data for this product in our Scientific Poster Library. Watch a Scientific Poster video of this product.
Application References(PubMed link indicates BioLegend citation): Parish CR, et al. 2009. Curr. Protoc. Immunol. Unit4.9. Miller MJ, et al. 2002. Science 296:1869. Tai LH, 2013. Clin Cancer Res. 19:5104. PubMed Svajger U, et al. 2014. J Lukoc Biol. 95:33. PubMed
Product Citations: Boland LK, et al. 2019. Front Immunol. 10:1080. PubMed Mews EA, et al. 2022. ACS Nano. 16:12185. PubMed Shen M, et al. 2022. Adv Sci (Weinh). 9:e2203523. PubMed Li L, et al. 2022. Cancer Immunol Res. 10:1475. PubMed Nasiri F, et al. 2023. Front Immunol. 14:1063838. PubMed Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed Bayat H, et al. 2023. Mol Ther Nucleic Acids. 32:432. PubMed Wu C, et al. 2023. Cancer Metab. 11:7. PubMed Romo ML, et al. 2023. PLoS Negl Trop Dis. 17:e0011386. PubMed Wang Z, et al. 2023. Mediators Inflamm. 2023:9810733. PubMed Labadie KP, et al. 2023. Cancer Gene Ther. . PubMed Ennis S, et al. 2023. iScience. 26:106943. PubMed Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed Nalbandian M, et al. 2022. Life Sci Alliance. 5: . PubMed Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed Liang Y, et al. 2022. Theranostics. 12:7729. PubMed Tang M, et al. 2022. Biomolecules. 12: . PubMed Zhang Z, et al. 2023. J Transl Med. 21:23. PubMed Vondra S, et al. 2023. Cell Rep. 42:111977. PubMed Garcia-Becerra N, et al. 2023. Cancers (Basel). 15: . PubMed Lin CP, et al. 2023. EMBO J. 42:e111614. PubMed Wang R, et al. 2023. iScience. 26:105954. PubMed Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed Sheng YR, et al. 2022. Cell Mol Life Sci. 79:173. PubMed Li Y, et al. 2022. Transl Oncol. 21:101424. PubMed Page N, et al. 2018. Immunity. 48:937. PubMed Zupancic E, et al. 2017. Journal of Controlled Release. 10.1016/j.jconrel.2017.05.014. PubMed Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed Boyt DT, et al. 2020. J R Soc Interface. 17:20190815. PubMed Wen Y, et al. 2020. J Invest Dermatol. . PubMed Hickey A, et al. 2021. Front Microbiol. 12:653587. PubMed Pires D, et al. 2021. Front Immunol. 12:742822. PubMed Sawada J, et al. 2021. Am J Pathol. 191:396. PubMed Hui CW, et al. 2022. Front Immunol. 13:919854. PubMed Nguyen DT, et al. 2022. Cells. 11:. PubMed Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed Rennier K, et al. 2020. Clin Cancer Res. 26:5019. PubMed Just S, et al. 2016. Sci Rep. 6:39796. PubMed Chen X, et al. 2021. Cell Death Differ. 28:1237. PubMed Chen M, et al. 2021. Cancers (Basel). 13:. PubMed Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed Saito S, et al. 2020. Nutrients. 12:. PubMed Deng H, et al. 2021. J Asthma Allergy. 14:839. PubMed Onodera T, et al. 2015. Sci Rep. 5:16801. PubMed Jones N, et al. 2021. Nat Commun. 12:1209. PubMed Guo HZ, et al. 2021. Sci Adv. 7:eabg4167. PubMed Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed Coray M, et al. 2022. Int J Mol Sci. 23:. PubMed Moser B, et al. 2021. Mol Cancer. 20:16. PubMed Zhao J, et al. 2021. Front Immunol. 12:658420. PubMed Hawila E, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.104. PubMed Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed Zhou L, et al. 2020. Clin Cancer Res. 26:290. PubMed Sertori R, et al. 2022. Front Immunol. 13:928252. PubMed Lv M, et al. 2020. Cell Res. 30:966. PubMed Codo AC, et al. 2020. Cell Metab. 32:437. PubMed Lerrer S, et al. 2021. iScience. 24:103020. PubMed Di Buduo CA, et al. 2021. eLife. 10:00. PubMed Yang Q, et al. 2020. Theranostics. 6.2375. PubMed Lu Z, et al. 2022. Nat Commun. 13:6623. PubMed Stinson WA, et al. 2022. JCI Insight. 7:. PubMed Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed Krueger CC, et al. 2019. Front Immunol. 10:1831. PubMed Monteran L, et al. 2022. Nat Commun. 13:5797. PubMed Stirling ER, et al. 2022. J Immunother Cancer. 10:. PubMed Wei C, et al. 2016. Cell Death Dis. 7:e2489. PubMed Shifrut E et al. 2018. Cell. 175(7):1958-1971 . PubMed Luo Q, et al. 2020. Cancer Sci. 111:4000. PubMed Rodriguez RM, et al. 2019. Cell Rep. 29:860. PubMed Tian M, et al. 2021. Elife. 10:. PubMed Kanemaru H, et al. 2021. iScience. 24:103067. PubMed Fassler M, et al. 2021. J Neuroinflammation. 18:19. PubMed Beghelli D, et al. 2017. Oxid Med Cell Longev. 10.1155/2017/7468064. PubMed Mercer F, et al. 2016. PLoS Negl Trop Dis. 10: 0004913. PubMed Burand AJ, et al. 2020. Front Immunol. 11:143. PubMed Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed Clement CC, et al. 2021. Immunity. 54:721. PubMed Feng Y, et al. 2022. Life (Basel). 12:. PubMed Kwiecinski JM, et al. 2021. Cell Rep. 36:109462. PubMed Ho JY, et al. 2021. Mol Ther Methods Clin Dev. 21:237. PubMed Kwee BJ, et al. 2019. Sci Adv. 5:eaav6313. PubMed Wettersten HI, et al. 2019. Cancer Res. 79:5048. PubMed Xie X, et al. 2021. Front Immunol. 12:625808. PubMed Brockman QR, et al. 2022. JCI Insight. :. PubMed Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed Chang T, et al. 2020. Aging (Albany NY). 12:21147. PubMed Lim J, et al. 2020. Sci Adv. 6:eaba1334. PubMed Chen W, et al. 2019. Arterioscler Thromb Vasc Biol. 39:2028. PubMed Montel‐Hagen A et al. 2019. Cell stem cell. 24(3):376-389 . PubMed Pires D, et al. 2021. Front Immunol. 12:647728. PubMed Sung J, et al. 2015. J Infect Dis. 212: 258 - 263. PubMed Soloff A, et al. 2017. J Appl Toxicol. 10.1002/jat.3465. PubMed Sen S, et al. 2018. J Immunol. 201:440. PubMed Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed Konda P, et al. 2022. Am J Cancer Res. 12:210. PubMed Rossnagl S, et al. 2016. PLoS Biol. 14: 1002562. PubMed Georgouli M et al. 2019. Cell. 176(4):757-774 . PubMed Ward D, et al. 2016. Haematologica. 101: 286 - 296. PubMed Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed Barsheshet Y, et al. 2017. Proc Natl Acad Sci U S A. 114:6086. PubMed Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed Lhuillier C, et al. 2021. J Clin Invest. 131:. PubMed Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed Kwantwi LB, et al. 2021. Bioengineered. 12:6996. PubMed Bonaccorsi-Riani E, et al. 2015. PLoS One. 10: 0136106. PubMed Ershaid N, et al. 2019. Nat Commun. 10:4375. PubMed Cao M, et al. 2021. Int J Cancer. 149:460. PubMed
Biology Area: Cell Biology, Cell Proliferation and Viability, Neuroscience
Antigen References: 1. Parish CR, et al. 2009. Curr. Protoc. Immunol. Unit4.9. 2. Lyons AB, 2000. J. Immunol. Methods 243:147.
Gene ID: NA
Regulatory Status: RUO
Other Names: 5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester Kit, CFDA SE Kit
Q: Can I use common compensation control for GFP, CFSE and FITC because they emit in the same channel?
A: It is not recommended even if they emit in the same channel because these are still different fluors with different brightness intensities. Individual compensation controls should be employed.